Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 1022-1029

  Cantaert, T ^a   De Rycke, L ^a   Mavragani, C P ^b   Wijbrandts, C A ^a   Niewold, T B ^b,c   Niers, T ^a   Vandooren, B ^a,d   Veys, E M ^d   Richel, D ^a   Tak, P P ^a   Crow, M K ^b   Baeten, D ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CASPASE 3 INHIBITOR; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; ETANERCEPT; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; INTERFERON; NUCLEOSOME ANTIBODY; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIBODY BLOOD LEVEL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL ASSAY; CELL DEATH; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; NEPHELOMETRY; NICK END LABELING; NUCLEOSOME; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; SYNOVITIS; SYNOVIUM; UPREGULATION;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; APOPTOSIS; AUTOANTIBODIES; COMPLEMENT C3; COMPLEMENT C4; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON TYPE I; MALE; MIDDLE AGED; NUCLEOSOMES; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHRITIS; STATISTICS, NONPARAMETRIC; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTORS; YOUNG ADULT;

EID: 67449164836     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.093724     Document Type: Article

References (53)

1. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-1377 (Pubitemid 37075812)
2. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol 2007;95:83-110. (Pubitemid 47381589)
3. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 2006;203:393-400. (Pubitemid 43290848)
4. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201:1659-1667 (Pubitemid 40721009)
5. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-711 (Pubitemid 40395116)
6. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Wardemann H, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 2006;203:2255-2261 (Pubitemid 44498360)
7. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;202:321-331 (Pubitemid 41043827)
8. Denny MF, Chandaroy P, Killen PD, Caricchio R, Lewis EE, Richardson BC, et al. Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol 2006;176:2095-2104 (Pubitemid 43201656)
9. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNAassociated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-1177 (Pubitemid 41586947)
10. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-392 (Pubitemid 28357766)
11. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-1023 (Pubitemid 36418243)
12. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52:2192-2201 (Pubitemid 40994342)
13. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity 2007;26:205-213 (Pubitemid 46329436)
14. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005;52:61-72.
15. Shen C, Maerten P, Geboes K, Van AG, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005;115:250-259 (Pubitemid 40716048)
16. van den Brande JM, Braat H, Van Den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785 (Pubitemid 36666774)
17. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-551 (Pubitemid 46828489)
18. Gottenberg JE, Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie 2007;89:856-871 (Pubitemid 47008948)
19. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18:676-682 (Pubitemid 44635182)
20. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-1227
21. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434 (Pubitemid 36910021)
22. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-195 (Pubitemid 32113134)
23. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005;52:3898-3909 (Pubitemid 41798229)
24. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-2038 (Pubitemid 34894757)
25. Baeten D, Kruithof E, De Rycke L, Vandooren B, Wyns B, Boullart L, et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004;50:2931-2941 (Pubitemid 39209532)
26. D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 2004;255:409-418 (Pubitemid 38315283)
27. Holdenrieder S, Stieber P, Bodenmuller H, Fertig G, Furst H, Schmeller N, et al. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001;39:596-605. (Pubitemid 32725743)
28. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-1916 (Pubitemid 43877940)
29. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004. (Pubitemid 350262327)
30. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-2162 (Pubitemid 36959195)
31. Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-773 (Pubitemid 38850446)
32. Tracey D, Klareskog L, Sasso EH, Salfeld J, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Therapeut 2008;117:244-279
33. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25:383-392 (Pubitemid 44354221)
34. Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001;22:427-431 (Pubitemid 32709976)
35. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005;102:3372-3377 (Pubitemid 40328052)
36. Di Sabatino A., Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004;53:70-77 (Pubitemid 38083013)
37. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-1157 (Pubitemid 33022095)
38. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376-392 (Pubitemid 40431090)
39. Ringheanu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004;10:801-810 (Pubitemid 39545226)
40. ten Hove T, van Montfrans C, Peppelenbosch MP, Van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-211
41. Van Deventer SJ. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001;121:1242-1246
42. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007;27:5499-5513 (Pubitemid 47124402)
43. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006;65:57-63. (Pubitemid 41815640)
44. Flierman R, Daha MR. The clearance of apoptotic cells by complement. Immunobiology 2007;212:363-370 (Pubitemid 46825236)
45. Grossmayer GE, Munoz LE, Weber CK, Franz S, Voll RE, Kern PM, et al. IgG autoantibodies bound to surfaces of necrotic cells and complement C4 comprise the phagocytosis promoting activity for necrotic cells of SLE sera. Ann Rheum Dis 2008;67:1626-1632
46. Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Begh Weerman MA, Smeets TJ, et al. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum 2008;58:3330-3339
47. Jiang N, Reich CF III, Monestier M, Pisetsky DS. The expression of plasma nucleosomes in mice undergoing in vivo apoptosis. Clin Immunol 2003;106:139-147 (Pubitemid 36369408)
48. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5:694-697 (Pubitemid 29289434)
49. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-59 (Pubitemid 28242023)
50. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the cmer membrane tyrosine kinase. J Exp Med 2002;196:135-140 (Pubitemid 34747319)
51. Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, et al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:1003-1008 (Pubitemid 40909513)
52. Lutz HU. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 2007;29:287-294 (Pubitemid 47633143)
53. Peng Y, Kowalewski R, Kim S, Elkon KB. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol 2005;42:781-787 (Pubitemid 40489027)